PEG-FUD

PEG-FUD (PEGylated Functional Upstream Domain) is a PEGylated peptide-based fibronectin assembly inhibitor developed by researchers at the University of Wisconsin-Madison. Derived from the F1 adhesin protein of Streptococcus pyogenes (specifically the Functional Upstream Domain, also known as pUR4), PEG-FUD binds with high affinity to the 70 kDa N-terminal region of fibronectin. This binding potently inhibits fibronectin fibrillogenesis and subsequent extracellular matrix (ECM) deposition. In preclinical models of solid tumors, such as breast cancer, PEG-FUD disrupts the fibrotic tumor microenvironment, leading to reduced tumor growth, increased tumor cell apoptosis, and decreased adhesion-mediated signaling through alpha-5 integrin and focal adhesion kinase (FAK). Additionally, PEG-FUD is being investigated as an anti-fibrotic therapeutic for renal fibrosis and other chronic inflammatory diseases.

Other names

PEG-pUR4PEG-pUR-4PEG-pUR 4PEGylated FUDPEGylated Functional Upstream DomainPEGylated Functional Upstream Domain peptidePEGylated pUR4